The Cooper Companies, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Albert G. White
- Full Time Employees
- 16,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 6101 Bollinger Canyon Road San Ramon CA United States of America 94583
- IPO Date
- Jan 21, 1983
- CIK
- 0000711404
- Website
- coopercos.com
- Similar Companies
- Business
- The Cooper Companies, Inc. (Nasdaq: COO) develops, manufactures, and markets a broad range of medical devices focused on vision care and women's health. The company operates through two primary business units: CooperVision, which produces soft contact lenses including daily, two-week, and monthly disposables for spherical, toric, multifocal, and presbyopia correction; and CooperSurgical, which provides fertility products, genomic solutions, contraception devices, reproductive care tools, birth-related instruments, women's and family health diagnostics, office and surgical devices such as INSORB staplers, Lone Star retractors, and Doppler blood flow monitors. Products are distributed to eye care practitioners, healthcare professionals, hospitals, clinics, group purchasing organizations, and authorized resellers worldwide. Founded in 1958 and headquartered in San Ramon, California, the company employs over 16,000 people across 130 countries in Europe, Asia, Africa, and the Americas. In August 2024, CooperSurgical acquired obp Surgical for approximately $100 million, adding the ONETRAC portfolio of single-use cordless surgical retractors with integrated multi-LED lighting and smoke evacuation, as well as cordless suction devices with radial LED lights, which generated $14.5 million in trailing twelve-month revenue and complement existing surgical offerings. This acquisition, expected to be neutral to non-GAAP earnings per share in fiscal 2024 and accretive thereafter, underscores ongoing strategic expansion in women's health and surgical devices; additionally, in September 2025, the board authorized a $2 billion stock repurchase program representing up to 15.4% of outstanding shares.
The Cooper Companies Inc (COO) Shares Surge 3.1% -- What GF Score of 84 Tells Investors
New Era Energy & Digital Announces Leadership Transition to Support Next Phase of Execution and Growth
CooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure
How COO Is Balancing Premium Lens Growth Against Asia-Pacific Risks?
How COO Is Riding Myopia and Fertility Trends Amid Execution Risks
The Cooper Companies (COO) is a Top-Ranked Value Stock: Should You Buy?
What Does the Sale of Slide Insurance Stock Worth $343,000 by the COO Mean for Investors?
Here's Why The Cooper Companies (COO) is a Strong Growth Stock
SoundHound AI's COO Sells 65K Shares
Here's Why The Cooper Companies (COO) is a Strong Momentum Stock
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
SpaceX COO Shotwell says Tesla tie-up ‘might make Elon's life a little easier'
Why The Cooper Companies (COO) is a Top Growth Stock for the Long-Term
The Cooper Companies: I Can See A Potential Upgrade On The Horizon
COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing
The Cooper Companies (COO) Reliance on International Sales: What Investors Need to Know
The Cooper Companies (COO) Beats Q2 Earnings and Revenue Estimates
CooperCompanies Announces Second Quarter 2026 Results
The Cooper Companies Gears Up to Post Q2 Earnings: What's in Store?
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie